Literature DB >> 21383702

Fearful of Avastin's fate, Genentech asks for unusual hearing.

Mark Ratner.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21383702     DOI： 10.1038/nm0311-233

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  1 in total

1.  Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.

Authors:  Robert Gray; Suman Bhattacharya; Christopher Bowden; Kathy Miller; Robert L Comis
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
  1 in total
  2 in total

Review 1.  Reappraising antiangiogenic therapy for breast cancer.

Authors:  Robert S Kerbel
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

2.  Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.

Authors:  Danfang Zhang; Baocun Sun; Xiulan Zhao; Yuemei Ma; Ru Ji; Qiang Gu; Xueyi Dong; Jing Li; Fang Liu; Xiaohua Jia; Xue Leng; Chong Zhang; Ran Sun; Jiadong Chi
Journal:  Mol Cancer       Date:  2014-09-08       Impact factor: 27.401
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.